Clinical characteristics, time course, treatment and outcomes of patients with immune checkpoint inhibitor-associated myocarditis

BACKGROUND: Immune checkpoint inhibitors (ICI) have emerged as a front-line therapy for a variety of solid tumors. With the widespread use of these agents, immune-associated toxicities are increasingly being recognized, including fatal myocarditis. There are limited data on the outcomes and prognost...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:J Immunother Cancer
Autors principals: Puzanov, Igor, Subramanian, Poornima, Yatsynovich, Yan V, Jacobs, David M, Chilbert, Maya R, Sharma, Umesh C, Ito, Fumito, Feuerstein, Steven G, Stefanovic, Filip, Switzer, Benjamin, Hicar, Mark D, Curtis, Anne B, Spangenthal, Edward J, Dy, Grace K, Ernstoff, Marc S, Vachhani, Pankit, Page, Brian J, Agrawal, Nikhil, Khunger, Arjun, Kapoor, Ankita, Hattoum, Alexander, Schentag, Jerome J
Format: Artigo
Idioma:Inglês
Publicat: BMJ Publishing Group 2021
Matèries:
Clinical/Translational Cancer Immunotherapy
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC8231054/
https://ncbi.nlm.nih.gov/pubmed/34162715
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/jitc-2021-002553
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars